TrimRX
US$ 29.42
glp 1 agonist benefits Frontiers Frontiers | Exploring the multifaceted
Description
Since the FDA approved Wegovy in 2021 and Zepbound in 2023, public awareness of GLP-1 drugs have surged
A recent in vivo study in healthy subjects showed that acute intravenous infusion of GLP-1 during a pancreatic clamp, in which insulin and glucagon levels were maintained at basal levels, caused a reduction in hepatic glucose production, suggesting a potential direct effect on gluconeogenesis [11]
The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent
Prescribing information: OZEMPIC (semaglutide) injection, for subcutaneous use
